NASDAQ:VSTM - Verastem Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$8.83 +0.07 (+0.80 %)
(As of 09/19/2018 04:00 PM ET)
Previous Close$8.76
Today's Range$8.67 - $9.03
52-Week Range$2.77 - $10.35
Volume2.10 million shs
Average Volume1.76 million shs
Market Capitalization$657.91 million
P/E Ratio-5.05
Dividend YieldN/A
Beta2.63
Verastem logoVerastem, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K) signaling pathways. The company's lead FAK inhibitor is defactinib, an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. Its defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. The company also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with hematologic cancers through the dual inhibition of PI3K delta and gamma. Its duvelisib is in Phase 3 randomized and late-and mid-stage clinical trials for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, as well as completed the Phase 2 study for the treatment of patients with double-refractory indolent non-Hodgkin lymphoma. The company has license agreements with Infinity Pharmaceuticals, Inc.; and Pfizer, Inc. Verastem, Inc. was founded in 2010 and is headquartered in Needham, Massachusetts.

Receive VSTM News and Ratings via Email

Sign-up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:VSTM
CUSIP92337C10
Phone781-292-4200

Debt

Debt-to-Equity Ratio0.19
Current Ratio7.70
Quick Ratio7.70

Price-To-Earnings

Trailing P/E Ratio-5.05
Forward P/E Ratio-5.89
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.19 per share
Price / Book7.42

Profitability

EPS (Most Recent Fiscal Year)($1.76)
Net Income$-67,800,000.00
Net MarginsN/A
Return on Equity-122.36%
Return on Assets-81.96%

Miscellaneous

Employees69
Outstanding Shares73,590,000
Market Cap$657.91 million

Verastem (NASDAQ:VSTM) Frequently Asked Questions

What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

How were Verastem's earnings last quarter?

Verastem Inc (NASDAQ:VSTM) announced its quarterly earnings data on Wednesday, August, 8th. The biopharmaceutical company reported ($0.30) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.33) by $0.03. The biopharmaceutical company had revenue of $10 million for the quarter. View Verastem's Earnings History.

When is Verastem's next earnings date?

Verastem is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for Verastem.

What price target have analysts set for VSTM?

9 analysts have issued 12-month target prices for Verastem's shares. Their predictions range from $10.00 to $17.00. On average, they anticipate Verastem's stock price to reach $14.4444 in the next year. This suggests a possible upside of 63.6% from the stock's current price. View Analyst Price Targets for Verastem.

What is the consensus analysts' recommendation for Verastem?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verastem.

What are Wall Street analysts saying about Verastem stock?

Here are some recent quotes from research analysts about Verastem stock:
  • 1. Cann analysts commented, "Verastem’s loss per share of $0.30 was in line with our estimated $0.30. There was an unanticipated upfront payment from Yakult of $10 million, in association with a collaboration agreement. This was offset by higher than estimated operating expense. SG&A of $15.8 million was higher than our estimated $90.0 million due to infrastructure ramp in association with the anticipated launch of Duvelisib in Q4 2018. R&D of $12.4 million exceeded our estimated $10.6 million due to further development of Duvelisib." (8/9/2018)
  • 2. According to Zacks Investment Research, "Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. " (7/20/2018)
  • 3. HC Wainwright analysts commented, "Olga Smolentseva, Ph.D. – (646-975-6966) / [email protected] Our Takeaways From Verastem Investor Day; Reiterate Buy We anticipate duvelisib approval in 4Q18. On May 2, Verastem Oncology held an Analyst and Investor Day in New York and provided an overview on duvelisib’s development and management’s plans for the drug’s commercial launch. Recall, on February 7, Verastem filed a NDA application for duvelisib, the company’s dual PI3K-γ/δ inhibitor, for the treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (r/r CLL/ SLL). The company has also filed for an accelerated approval of duvelisib for the treatment of follicular lymphoma (FL). We note that the FDA has granted a priority review for the duvelisib application, with the PDUFA date scheduled for October 5." (5/3/2018)
  • 4. Cantor Fitzgerald analysts commented, "Working off Overhangs. We think VSTM shares are undervalued relative to the duvelisib opportunity, and this is partly a function, in our view, of overhangs, particularly cash. VSTM had just under $87 mln in cash, which is sufficient to fund the company into 2H18, but will need additional capital to see duvelisib through commercialization. VSTM has an additional $35 mln available under a debt facility, and the company could add additional cash through a partner deal. It has been our anticipation that VSTM will need to address the capital markets in some way in 2018." (3/13/2018)

Are investors shorting Verastem?

Verastem saw a decline in short interest in the month of August. As of August 15th, there was short interest totalling 6,015,546 shares, a decline of 17.7% from the July 31st total of 7,309,468 shares. Based on an average daily volume of 2,132,691 shares, the short-interest ratio is currently 2.8 days. Approximately 8.4% of the company's shares are short sold. View Verastem's Current Options Chain.

Who are some of Verastem's key competitors?

Who are Verastem's key executives?

Verastem's management team includes the folowing people:
  • Mr. Robert Forrester, Pres, CEO & Director (Age 54)
  • Dr. NgocDiep T Le M.D., Ph.D., Chief Medical Officer (Age 50)
  • Mr. Richard H. Aldrich, Founder and Consultant (Age 64)
  • Dr. Robert A. Weinberg, Co-Founder and Chair of Scientific Advisory Board
  • Dr. Piyush B. Gupta, Co-Founder

Has Verastem been receiving favorable news coverage?

News articles about VSTM stock have been trending somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Verastem earned a daily sentiment score of 0.18 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 46.57 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Verastem.

Who are Verastem's major shareholders?

Verastem's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (5.51%), BlackRock Inc. (4.83%), Renaissance Technologies LLC (1.45%), Northern Trust Corp (0.85%), International Biotechnology Trust PLC (0.68%) and EAM Investors LLC (0.83%). Company insiders that own Verastem stock include Joseph M Lobacki, Steven H Bloom and Timothy J Barberich. View Institutional Ownership Trends for Verastem.

Which major investors are selling Verastem stock?

VSTM stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, GSA Capital Partners LLP, Millennium Management LLC, ClariVest Asset Management LLC and Victory Capital Management Inc.. View Insider Buying and Selling for Verastem.

Which major investors are buying Verastem stock?

VSTM stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., Northern Trust Corp, EAM Investors LLC, Bank of New York Mellon Corp, Bank of New York Mellon Corp, EAM Global Investors LLC and Sei Investments Co.. Company insiders that have bought Verastem stock in the last two years include Joseph M Lobacki, Steven H Bloom and Timothy J Barberich. View Insider Buying and Selling for Verastem.

How do I buy shares of Verastem?

Shares of VSTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Verastem's stock price today?

One share of VSTM stock can currently be purchased for approximately $8.83.

How big of a company is Verastem?

Verastem has a market capitalization of $657.91 million. The biopharmaceutical company earns $-67,800,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Verastem employs 69 workers across the globe.

How can I contact Verastem?

Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The biopharmaceutical company can be reached via phone at 781-292-4200 or via email at [email protected]em.com.


MarketBeat Community Rating for Verastem (NASDAQ VSTM)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  346 (Vote Outperform)
Underperform Votes:  216 (Vote Underperform)
Total Votes:  562
MarketBeat's community ratings are surveys of what our community members think about Verastem and other stocks. Vote "Outperform" if you believe VSTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VSTM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel